Research teams and research areas

The Institut de la Vision brings together nearly 300 researchers in 18 research units specialized in ophthalmological pathologies. At the forefront of scientific innovation, these units conduct translational research aimed at developing cutting-edge technological solutions and therapeutic innovations for the prevention, diagnosis and treatment of these pathologies. Organized around five strategic research axes, the teams of the Institut de la Vision cover a wide range of topics, from the molecular physiology of vision to innovative therapeutic approaches.

Inflammation and Immunology in Retinal Diseases

Our team studies the inflammatory mechanisms that lead to neuronal degeneration and vascular remodeling in age-related macular disease, diabetic retinopathy, and non-infectious uveitis.

Florian Sennlaub Reaserch director
View profile
Michel Paques MD, PhD
View profile

Presentation

The retina, is considered “immune privileged”, meaning that innate and adaptive immune responses are dampened or suppressed, possibly because it is particularly vulnerable to immunopathogenic collateral damage, as it has very limited regenerative capacities, and the irreversible damage to the retina and vision puts the fitness of the individual at risk. Nevertheless, this immune privilege is relative and in diseases such as age-related macular degeneration (AMD) and diabetic retinopathy (DR), we observe the protracted accumulation of pathogenic mononuclear phagocytes (MPs), an over-activation of the innate immune system that is observed in diabetes and many age-related diseases. More dramatically, in non-infectious autoimmune uveitis (NIU), tissue damage is associated with the presence of autoreactive T-cells against retinal antigens, with secondary infiltration of pro-inflammatory MPs that are largely responsible for the tissue destruction that characterize this pathology. 

AMD and inflammation (Florian Sennlaub)

Recent evidence suggests an implication of inflammatory mediators in AMD. We have focused our interest on the role of microglial cells (MC) and mononuclear phagocyte (MP) in this condition. Our data indicates that:

  • MC/MP accumulate in affected areas of the macula in human AMD
  • MC/MP accumulate leads to/contributes to Drusen formation, retinal degeneration and exacerbated neovascularization, similarly to AMD. Our data suggests an important role of subretinal MC and MP accumulation in the development of AMD. Inhibiting subretinal inflammation in AMD is a promising avenue to develop new efficient therapies.

Diabetic retinopathy and inflammation (Xavier Guillonneau)

Diabetic Retinopathy (DR) affects more than 60% of people with type 2 diabetes. Non-proliferative DR (NPDR), the earliest stage of DR, is characterized by retinal inflammation and the progressive degeneration of retinal capillaries, breakdown of the blood-retinal barrier and extravasation of plasma content in the retina. NPDR is followed by pathological neovascularization and further neuronal degeneration. Dyslipidemia is a RD risk factor independent of hyperglycemia. We analyze the consequence of lipid plasma retinal extravasion on the activation of Mononuclear phagocyte (MP) and glial cells. We aim at (i) characterizing the molecular mechanisms linking lipid-derived activation of MP and glia to vascular remodeling, (ii) at identifying plasma pathogenic lipids specific of DR patients and (iii) developing innovative therapy to normalize lipid-derived MP and glial activation.

Non-infectious uveitis (Cécile Delarasse)

Non-infectious uveitis is an inflammatory pathology of the eye that affects the uvea (anterior and intermediate uveitis) but also the retina (posterior uveitis). Both innate and adaptive immune systems are involved in the pathological processes. Our aim is 1) to identify and validate new therapeutic targets using animal models of autoimmune uveitis, 2) to understand the specific mechanisms of recruitment and activation of microglia (MC) and mononuclear phagocyte (MP) in the retina during uveitis, and 3) to characterize the immune response in a prospective cohort study of patients with non-infectious uveitis.

Research areas

  • Determine inflammatory state of immune cells in cohorts of AMD, DR and NIU patients

  • Develop AMD models based on the consequences of genetic risk factors and clinical findings

  • Decipher how the cholinergic anti-inflammatory pathway and the inflammatory reflex control phagocyte mobilization and function in retinal inflammation

  • Study how systemic plasma signals determine macroglia polarization

  • Determine similarities and differences in MP and microglia polarization in DR, AMD, and NIU using deep immunophenotyping

Team members

Michel Paques MD, PhD
View profile
Xavier Guillonneau Principal Investigator
View profile
Cécile Delarasse Principal Investigator
View profile
Sara Touhami
View profile
Aude Couturier
View profile
Thibaud Mathis MD, PhD
View profile
Sébastien Augustin
View profile
Lauriane Przegralek
View profile
Foteini Argyriou
View profile
Caroline Nous
View profile
Anastasiia Novikova
View profile
Remi Karadayi Postdoctoral Researcher
View profile
Kaitryn Ronning Postdoctoral Researcher
View profile
Paul-Alexandre Dechelle-Marquet
View profile
Yueshen Che
View profile
Polina Malahov
View profile
Yashvi Bhat
View profile
Avtar Sain
View profile
Camille Roux
View profile
Gabriella Florez
View profile

Scientific publications

Below you will find the latest scientific publications in this field: Inflammation and Immunology in Retinal Diseases.

Shedding light on myopia by studying complete congenital stationary night blindness. Progress in retinal and eye research

Zeitz C; Roger JE; Audo I; Michiels C; Sánchez-Farías N; Varin J; Frederiksen H; Wilmet B; Callebert J; Gimenez ML et al.
2023-01 | Journal article DOI: 10.1016/j.preteyeres.2022.101155 PMID: 36669906

Perilipin 2-positive mononuclear phagocytes accumulate in the diabetic retina and promote PPARγ-dependent vasodegeneration

Blot G, Karadayi R, Przegralek L, Sartoris TM, Charles-Messance H, Augustin S, Negrier P, Blond F, Muñiz-Ruvalcaba FP, Rivera-de la Parra D, Vignaud L, Couturier A, Sahel JA, Acar N, Jimenez-Corona A, Delarasse C, Garfias Y, Sennlaub F, Guillonneau X.
J Clin Invest. 2023 Oct 2;133(19):e161348. doi: 10.1172/JCI161348

P2X7-dependent immune pathways in retinal diseases.

Déchelle-Marquet PA; Guillonneau X; Sennlaub F; Delarasse C
Neuropharmacology 2022-11 | Journal article DOI: 10.1016/j.neuropharm.2022.109332 PMID: 36372269

FoxP3 expression by retinal pigment epithelial cells: transcription factor with potential relevance for the pathology of age-related macular degeneration.

Alfaar AS; Stürzbecher L; Diedrichs-Möhring M; Lam M; Roubeix C; Ritter J; Schumann K; Annamalai B; Pompös IM; Rohrer B et al.
Journal of neuroinflammation 2022-10 | Journal article DOI: 10.1186/s12974-022-02620-w PMID: 36273134 PMC: PMC9588251

Long Term Time-Lapse Imaging of Geographic Atrophy: A Pilot Study.

Paques M; Norberg N; Chaumette C; Sennlaub F; Rossi E; Borella Y; Grieve K
Frontiers in medicine 2022-06 | Journal article DOI: 10.3389/fmed.2022.868163 PMID: 35814763 PMC: PMC9257004

Hypoxia Inhibits Subretinal Inflammation Resolution Thrombospondin-1 Dependently.

Touhami S; Béguier F; Yang T; Augustin S; Roubeix C; Blond F; Conart JB; Sahel JA; Bodaghi B; Delarasse C et al.
International journal of molecular sciences 2022-01 | Journal article DOI: 10.3390/ijms23020681 PMID: 35054863 PMC: PMC8775350

Job offers

Postdoctoral position available in Autoimmune response in Retinal disease

Type of contract : CDD - Published on : 15 May 2024
View this job offer

Contact

Fields marked with an asterisk (*) are mandatory.